Encompass Health (NYSE:EHC) PT Raised to $108.00 at Barclays

Encompass Health (NYSE:EHC) had its price objective boosted by analysts at Barclays from $101.00 to $108.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 30.97% from the stock’s current price.

Several other research firms have also commented on EHC. Stephens reiterated an “overweight” rating and set a $85.00 price objective on shares of Encompass Health in a research note on Tuesday, January 16th. Truist Financial boosted their price objective on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Wednesday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $83.00 price objective on shares of Encompass Health in a research note on Friday, February 9th. Finally, Mizuho boosted their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $86.56.

Encompass Health Stock Performance

NYSE EHC opened at $82.46 on Thursday. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 1.50 and a beta of 0.94. Encompass Health has a twelve month low of $57.55 and a twelve month high of $85.84. The company has a current ratio of 1.37, a quick ratio of 1.28 and a debt-to-equity ratio of 1.14. The stock has a 50-day moving average of $78.25 and a 200 day moving average of $70.87.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. Encompass Health’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.88 EPS. Sell-side analysts anticipate that Encompass Health will post 4.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

A number of large investors have recently made changes to their positions in EHC. International Assets Investment Management LLC purchased a new position in Encompass Health in the fourth quarter worth approximately $20,210,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in Encompass Health by 2.3% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock worth $87,989,000 after acquiring an additional 29,926 shares during the period. Phocas Financial Corp. grew its position in Encompass Health by 112.4% in the fourth quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock worth $6,664,000 after acquiring an additional 52,847 shares during the period. Nordea Investment Management AB grew its position in Encompass Health by 21.0% in the fourth quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock worth $6,787,000 after acquiring an additional 17,684 shares during the period. Finally, Oak Thistle LLC grew its position in Encompass Health by 19.1% in the fourth quarter. Oak Thistle LLC now owns 14,436 shares of the company’s stock worth $963,000 after acquiring an additional 2,319 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.